These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 1412138)

  • 21. [Treatment of vascular diseases of the extremities using pentoxifylline].
    Di Perri T
    Ric Clin Lab; 1988; 18 Suppl 2():49-56. PubMed ID: 3073515
    [No Abstract]   [Full Text] [Related]  

  • 22. Phosphorus nuclear magnetic resonance: a non-invasive technique for the study of muscle bioenergetics during exercise.
    Sapega AA; Sokolow DP; Graham TJ; Chance B
    Med Sci Sports Exerc; 1987 Aug; 19(4):410-20. PubMed ID: 3309542
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [The effect of hyper- and hypothyroidism on the energy metabolism of skeletal muscles--a study using 31P-magnetic resonance spectroscopy].
    Moka D; Theissen P; Linden A; Waters W; Schicha H
    Nuklearmedizin; 1991 Jun; 30(3):77-83. PubMed ID: 1871006
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Tolerance and therapeutic results of iloprost in obliterative arteriopathy in lower limbs at the severe chronic ischemia stage. A retrospective study of 29 consecutive cases].
    Duthois S; Cailleux N; Lévesque H
    J Mal Vasc; 2000 Feb; 25(1):17-26. PubMed ID: 10705132
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The significance of vasodilator therapy in obliterative arterial disease.
    Thulesius O
    Scand J Clin Lab Invest Suppl; 1967; 99():222-4. PubMed ID: 6056925
    [No Abstract]   [Full Text] [Related]  

  • 26. Objective evaluation of cyclandelate in treatment of intermittent claudication associated with arteriosclerosis obliterans.
    Ross JV
    Vasc Dis; 1965 Sep; 2(5):300-4. PubMed ID: 5866204
    [No Abstract]   [Full Text] [Related]  

  • 27. Nuclear magnetic resonance studies on the mechanism of regulation of glycogenolysis in contracting skeletal muscle.
    Sugi H; Yamada T
    Biomed Biochim Acta; 1989; 48(5-6):S335-40. PubMed ID: 2787984
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [The medical treatment of chronic arteriopathies of the lower extremities and its limitations].
    Aubert M
    Angeiologie; 1964; 16(6):17-25. PubMed ID: 5877972
    [No Abstract]   [Full Text] [Related]  

  • 29. [Visualizing muscular phosphorus metabolites in peripheral arterial occlusive disease].
    Rexroth W; Semmler W; Gückel F; Stadtlander M; von Kaick G; Hild R
    Vasa Suppl; 1988; 23():115-20. PubMed ID: 3206329
    [No Abstract]   [Full Text] [Related]  

  • 30. Metabolic changes in reflex sympathetic dystrophy: a 31P NMR spectroscopy study.
    Heerschap A; den Hollander JA; Reynen H; Goris RJ
    Muscle Nerve; 1993 Apr; 16(4):367-73. PubMed ID: 8455649
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Stability of high-energy substrates in fast- and slow-twitch muscle: comparison of enzymatic assay of biopsy with in vivo 31P nuclear magnetic resonance spectroscopy.
    Madapallimattam AG; Cross A; Nishio ML; Jeejeebhoy KN
    Anal Biochem; 1994 Feb; 217(1):103-9. PubMed ID: 8203725
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Further trials of a long-acting vasodilator agent in 397 patients with cronic peripheral obliterating arteriopathy of a sclerotic nature].
    Ghezzi P; Cavaliere P; Berti Riboli E
    Minerva Cardioangiol; 1969 May; 17(5):333-6. PubMed ID: 5785731
    [No Abstract]   [Full Text] [Related]  

  • 33. The compartment syndrome. An experimental and clinical study of muscular energy metabolism using phosphorus nuclear magnetic resonance spectroscopy.
    Heppenstall RB; Sapega AA; Scott R; Shenton D; Park YS; Maris J; Chance B
    Clin Orthop Relat Res; 1988 Jan; (226):138-55. PubMed ID: 3275510
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [New information on obliterative disease of the peripheral vessels and its treatment].
    Masek O
    Vnitr Lek; 1968 Mar; 14(3):301-3. PubMed ID: 5638968
    [No Abstract]   [Full Text] [Related]  

  • 35. Peripheral vasodilator drugs.
    Br Med J; 1969 Jul; 3(5661):38-40. PubMed ID: 5787285
    [No Abstract]   [Full Text] [Related]  

  • 36. [Experiences with the treatment of peripheral vascular diseases with Xavin].
    Brücknerová O
    Vnitr Lek; 1973 Apr; 19(4):379-86. PubMed ID: 4699159
    [No Abstract]   [Full Text] [Related]  

  • 37. Muscle energy metabolism in Duchenne dystrophy studied by 31P-NMR: controlled trials show no effect of allopurinol or ribose.
    Griffiths RD; Cady EB; Edwards RH; Wilkie DR
    Muscle Nerve; 1985; 8(9):760-7. PubMed ID: 3935926
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Evaluation of delayed-action Tebonin with the study of muscle flow, using xenon 133].
    Matteoni R; Reale R; Lauri D; Sirolli C; Tata MV
    Minerva Cardioangiol; 1973 Apr; 21(4):264-71. PubMed ID: 4710123
    [No Abstract]   [Full Text] [Related]  

  • 39. [Clinical trial of a long-acting vasodilator agent in chronic peripheral obliterating arteriopathy of a sclerotic nature].
    Gemma GB; Ghezzi P; Cavaliere P
    Minerva Cardioangiol; 1969 May; 17(5):324-32. PubMed ID: 5785730
    [No Abstract]   [Full Text] [Related]  

  • 40. Regression of peripheral atherosclerosis during therapy with high doses of nicotinic acid.
    Ost CR; Sténson S
    Scand J Clin Lab Invest Suppl; 1967; 99():241-5. PubMed ID: 6056927
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.